Allogeneic bone marrow transplantation.
Allogeneic bone marrow transplantation (BMT) after high-dose, marrow-ablative chemoradiotherapy has been established as the treatment of choice for various hematologic, neoplastic, and congenital disorders. The most common type of marrow graft is an allogeneic one from a sibling donor who has compatible human leukocyte antigen (HLA). Only 30% of patients requiring allogeneic BMT have an HLA-compatible sibling donor. Over the past few years, marrows from unrelated HLA-compatible donors have been used with increasing frequency and promising outcome in certain hematologic malignancies. Despite the morbidity and mortality associated with this treatment modality, allogeneic BMT may provide a 20% to 90% chance of long-term, disease-free survival to patients with a wide variety of neoplastic and abnormal marrow disorders.
Tabbara
I A
IA
Bone Marrow Transplant Program, George Washington University School of Medicine, Washington, DC 20037, USA.
D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D001855:Bone Marrow Diseases / Q000628:therapy; D016465:Bone Marrow Purging / Q000379:methods; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D018572:Disease-Free Survival; D006680:HLA Antigens / Q000235:genetics; D006402:Hematologic Diseases / Q000628:therapy; D006648:Histocompatibility; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D006680:HLA Antigens